After administering sublingual nitroglycerin for chest pain, what is the next best treatment for a patient with NSTEMI and low oxygen saturation?

After administering sublingual nitroglycerin for chest pain, what is the next best treatment for a patient with NSTEMI and low oxygen saturation?

• A. Administer oxygen supplementation.
• B. Administer IV beta-blockers.
• C. Administer morphine for pain relief.
• D. Administer an IV bolus of fondaparinux.

Answer: (D)

In the scenario described, the key concern is providing immediate care for a patient experiencing chest pain due to NSTEMI (non-ST elevation myocardial infarction) while also addressing their low oxygen saturation. Administering an IV bolus of fondaparinux is aimed at providing anticoagulation therapy, which is essential in the management of NSTEMI. Fondaparinux acts as a direct factor Xa inhibitor, helping to prevent further thrombus formation, which is critical in reducing the risk of adverse cardiac events in patients with NSTEMI. While providing oxygen supplementation can be important for patients with low oxygen saturation, it does not directly address the underlying pathophysiology of NSTEMI. Oxygen supplementation is typically utilized when there is significant hypoxemia, but the immediate life-threatening condition of NSTEMI requires anticoagulation to prevent further ischemic damage. Morphine is often used for pain relief, but its role in NSTEMI management primarily concerns pain control rather than addressing the coagulation issues. Additionally, while beta-blockers have a significant role in long-term management of NSTEMI, they are not the immediate priority in acute treatment, especially in the context of low oxygen saturation and the need for anticoagulation. Thus, administering

In the scenario described, the key concern is providing immediate care for a patient experiencing chest pain due to NSTEMI (non-ST elevation myocardial infarction) while also addressing their low oxygen saturation. Administering an IV bolus of fondaparinux is aimed at providing anticoagulation therapy, which is essential in the management of NSTEMI. Fondaparinux acts as a direct factor Xa inhibitor, helping to prevent further thrombus formation, which is critical in reducing the risk of adverse cardiac events in patients with NSTEMI.

While providing oxygen supplementation can be important for patients with low oxygen saturation, it does not directly address the underlying pathophysiology of NSTEMI. Oxygen supplementation is typically utilized when there is significant hypoxemia, but the immediate life-threatening condition of NSTEMI requires anticoagulation to prevent further ischemic damage.

Morphine is often used for pain relief, but its role in NSTEMI management primarily concerns pain control rather than addressing the coagulation issues. Additionally, while beta-blockers have a significant role in long-term management of NSTEMI, they are not the immediate priority in acute treatment, especially in the context of low oxygen saturation and the need for anticoagulation.

Thus, administering